The relationship between hippocampal amyloid beta burden and spatial distribution of neurofibrillary degeneration.

Alzheimer's disease amyloid beta image analysis neurodegeneration neurofibrillary degeneration primary age-related tauopathy tau

Journal

Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978

Informations de publication

Date de publication:
07 2023
Historique:
revised: 30 12 2022
received: 17 11 2022
accepted: 04 01 2023
medline: 27 7 2023
pubmed: 5 2 2023
entrez: 4 2 2023
Statut: ppublish

Résumé

Neurofibrillary degeneration in Alzheimer's disease (AD) typically involves the entorhinal cortex and CA1 subregion of the hippocampus early in the disease process, whereas in primary age-related tauopathy (PART), there is an early selective vulnerability of the CA2 subregion. Image analysis-based quantitative pixel assessments were used to objectively evaluate amyloid beta (Aβ) burden in the medial temporal lobe in relation to the distribution of hyperphosphorylated-tau (p-tau) in 142 cases of PART and AD. Entorhinal, CA1, CA3, and CA4 p-tau deposition levels are significantly correlated with Aβ burden, while CA2 p-tau is not. Furthermore, the CA2/CA1 p-tau ratio is inversely correlated with Aβ burden and distribution. In addition, cognitive impairment is correlated with overall p-tau burden. These data indicate that the presence and extent of medial temporal lobe Aβ may determine the distribution and spread of neurofibrillary degeneration. The resulting p-tau distribution patterns may discriminate between PART and AD. Subregional hyperphosphorylated-tau (p-tau) distribution is influenced by hippocampal amyloid beta burden. Higher CA2/CA1 p-tau ratio is predictive of primary age-related tauopathy-like neuropathology. Cognitive function is correlated with the overall hippocampal p-tau burden.

Identifiants

pubmed: 36738450
doi: 10.1002/alz.12966
doi:

Substances chimiques

Amyloid beta-Peptides 0
tau Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3158-3170

Subventions

Organisme : NIA NIH HHS
ID : P30 AG066444
Pays : United States
Organisme : NIA NIH HHS
ID : K01 AG070326
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG066519
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG072980
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG021055
Pays : United States
Organisme : NINDS NIH HHS
ID : U24 NS072026
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG072979
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG066468
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG003991
Pays : United States

Informations de copyright

© 2023 the Alzheimer's Association.

Références

Braak H, Del Tredici K. The pathological process underlying alzheimer's disease in individuals under thirty. Acta Neuropathol. 2011;121:171-181.
Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960-969.
Braak H, Braak E. Neuropathological stageing of alzheimer-related changes. Acta Neuropathol. 1991;82:239-259.
Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791-1800.
Montine TJ, Phelps CH, Beach TG, et al. National institute on aging-alzheimer's association guidelines for the neuropathologic assessment of alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123:1-11.
Iida MA, Farrell K, Walker JM, et al. Predictors of cognitive impairment in primary age-related tauopathy: an autopsy study. Acta Neuropathol Commun. 2021;9:134.
Walker JM, Richardson TE, Farrell K, et al. Early Selective Vulnerability of the CA2 hippocampal subfield in primary age-related tauopathy. J Neuropathol Exp Neurol. 2021;80:102-111.
Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128:755-766.
Jellinger KA. Different patterns of hippocampal tau pathology in alzheimer's disease and PART. Acta Neuropathol. 2018;136:811-813.
Iseki E, Tsunoda S, Suzuki K, et al. Regional quantitative analysis of NFT in brains of non-demented elderly persons: comparisons with findings in brains of late-onset Alzheimer's disease and limbic NFT dementia. Neuropathology. 2002;22:34-39.
Takayama N, Iseki E, Yamamoto T, Kosaka K. Regional quantitative study of formation process of neurofibrillary tangles in the hippocampus of non-demented elderly brains: comparison with late-onset alzheimer's disease brains. Neuropathology. 2002;22:147-153.
Robinson AC, Davidson YS, Roncaroli F, et al. Influence of APOE genotype in primary age-related tauopathy. Acta Neuropathol Commun. 2020;8:215.
Santa-Maria I, Haggiagi A, Liu X, et al. The MAPT H1 haplotype is associated with tangle-predominant dementia. Acta Neuropathol. 2012;124:693-704.
Duyckaerts C, Braak H, Brion JP, et al. PART is part of Alzheimer disease. Acta Neuropathol. 2015;129:749-756.
Jellinger KA, Alafuzoff I, Attems J, et al. PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol. 2015;129:757-762.
Farrell K, Iida MA, Cherry JD, et al. Differential vulnerability of hippocampal subfields in primary age-related tauopathy and chronic traumatic encephalopathy. J Neuropathol Exp Neurol. 2022.
Farrell K, Kim S, Han N, et al. Genome-wide association study and functional validation implicates JADE1 in tauopathy. Acta Neuropathol. 2022;143:33-53.
McKenzie AT, Marx GA, Koenigsberg D, et al. Interpretable deep learning of myelin histopathology in age-related cognitive impairment. Acta Neuropathol Commun. 2022;10:131.
Marx GA, Koenigsberg DG, McKenzie AT, et al. Artificial intelligence-derived neurofibrillary tangle burden is associated with antemortem cognitive impairment. Acta Neuropathol Commun. 2022;10:157.
Duvernoy H, Cattin F, Risold PY. Sectional anatomy and magnetic resonance imaging. In: Duvernoy H, Cattin F, Risold PY, eds. The Human Hippocampus: Functional Anatomy, Vascularization and Serial Sections with MRI. Springer-Verlag; 2013:129.
Walker JM, Fudym Y, Farrell K, et al. Asymmetry of hippocampal tau pathology in primary age-related tauopathy and alzheimer disease. J Neuropathol Exp Neurol. 2021;80:436-445.
Karanth S, Nelson PT, Katsumata Y, et al. Prevalence and clinical phenotype of quadruple misfolded proteins in older adults. JAMA Neurol. 2020;77:1299-1307.
Rabinovici GD, Carrillo MC, Forman M, et al. Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. Alzheimers Dement (N Y). 2016;3:83-91.
Savola S, Kaivola K, Raunio A, et al. Primary age-related tauopathy in a Finnish population-based study of the oldest old (Vantaa 85+). Neuropathol Appl Neurobiol. 2022;48:e12788.
Teylan M, Besser LM, Crary JF, et al. Clinical diagnoses among individuals with primary age-related tauopathy versus Alzheimer's neuropathology. Lab Invest. 2019;99:1049-1055.
Teylan M, Mock C, Gauthreaux K, et al. Cognitive trajectory in mild cognitive impairment due to primary age-related tauopathy. Brain. 2020;143:611-621.
Bell WR, An Y, Kageyama Y, et al. Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease. Alzheimers Dement. 2019;15:8-16.
Quintas-Neves M, Teylan MA, Morais-Ribeiro R, et al. Divergent magnetic resonance imaging atrophy patterns in Alzheimer's disease and primary age-related tauopathy. Neurobiol Aging. 2022;117:1-11.
Quintas-Neves M, Teylan MA, Besser L, et al. Magnetic resonance imaging brain atrophy assessment in primary age-related tauopathy (PART). Acta Neuropathol Commun. 2019;7:204.
Vogel JW, Young AL, Oxtoby NP, et al. Four distinct trajectories of tau deposition identified in Alzheimer's disease. Nat Med. 2021;27:871-881.
Walker JM, White CL, Farrell K, Crary JF, Richardson TE. Neocortical Neurofibrillary Degeneration in Primary Age-Related Tauopathy. J Neuropathol Exp Neurol. 2022;81:146-148.
Smirnov DS, Salmon DP, Galasko D, et al. TDP-43 Pathology Exacerbates Cognitive Decline in Primary Age-Related Tauopathy. Ann Neurol. 2022;92:425-438.
Chevaleyre V, Piskorowski RA. Hippocampal Area CA2: an Overlooked but Promising Therapeutic Target. Trends Mol Med. 2016;22:645-655.
Zeineh MM, Engel SA, Thompson PM, Bookheimer SY. Dynamics of the hippocampus during encoding and retrieval of face-name pairs. Science. 2003;299:577-580.
Ishizawa T, Ko LW, Cookson N, Davias P, Espinoza M, Dickson DW. Selective neurofibrillary degeneration of the hippocampal CA2 sector is associated with four-repeat tauopathies. J Neuropathol Exp Neurol. 2002;61:1040-1047.
Walker JM, Kazempour Dehkordi S, Fracassi A, et al. Differential protein expression in the hippocampi of resilient individuals identified by digital spatial profiling. Acta Neuropathol Commun. 2022;10:23.
Walker JM, Dehkordi SK, Schaffert J, et al. The Spectrum of Alzheimer-Type Pathology in Cognitively Normal Individuals. J Alzheimers Dis. 2022.
Leuzy A, Smith R, Cullen NC, et al. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. JAMA Neurol. 2022;79:149-158.
Pichet Binette A, Franzmeier N, Spotorno N, et al. Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease. Nat Commun. 2022;13:6635.
Crary JF. Primary age-related tauopathy and the amyloid cascade hypothesis: the exception that proves the rule. J Neurol Neuromedicine. 2016;1:53-57.

Auteurs

Jamie M Walker (JM)

Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Neuropathology Brain Bank & Research CoRE, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

William Goette (W)

Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Kurt Farrell (K)

Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Neuropathology Brain Bank & Research CoRE, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Department of Artificial Intelligence & Human Health, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Megan A Iida (MA)

Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Neuropathology Brain Bank & Research CoRE, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
School of Medicine, University of Michigan, Ann Arbor, Michigan, USA.

Esma Karlovich (E)

Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Neuropathology Brain Bank & Research CoRE, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Department of Pathology and Cell Biology, Columbia University, New York, New York, USA.
The PART working group is a multi-institutional collaboration. PART working group investigators are listed in the acknowledgments section.

Charles L White (CL)

Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

John F Crary (JF)

Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Neuropathology Brain Bank & Research CoRE, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Department of Artificial Intelligence & Human Health, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Timothy E Richardson (TE)

Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Neuropathology Brain Bank & Research CoRE, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH